Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Signs $29M in New Licensing Deals

NEW YORK, Feb. 24 (GenomeWeb News) - Accelrys yesterday said that in the three months ending Dec. 31, 2005, it entered into "a number of comprehensive, multi-year agreements with some of the world's largest pharmaceutical companies."

The agreements include licenses for Accelrys' computational software and informatics platform totaling $29 million over the term of the agreements, said Accelrys in a statement.

The agreements have durations of two to five years.

No further details were released.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.